Abstract 287P
Background
Nasopharyngeal carcinoma (NPC) has a high incidence among malignant tumors in China, accounting for the highest incidence of head and neck tumors. The treatment of recurrent NPC is difficult, and both the traditional in vitro cell line and PDX models have obvious shortcomings. Therefore, it is imperative to establish better disease models, to study further the mechanism of recurrent NPC, and to explore a more effective treatment method. Tumor organoids are tumor micro-organs in which stem cells are cultured in 3D in vitro. They have been verified by histopathology, molecular biology and genomics, and can retain most of the biological characteristics and tumor heterogeneity of primary tumors, which could be the best models for basic and clinical research. This study aimed to culture and identify NPC organoids using NPC biopsy and resected tissues.
Methods
Fifteen fresh nasopharygeal cancer tissue samples (diagnosed by pathology)were collected from NanFang hospital for 3D culture from June 2018 to December 2019. NPC organoids were collected, fixed with 10% formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. The expression of CD133/CD44/CD47/BMI-1/EBER were detected by immunohistochemistry and in situ hybridization.
Results
1.Successful establishment of nasopharyngeal carcinoma organoid culture system. A total of 50 NPC samples were collected, and 29 organoids were successfully cultured, with a success rate of 58%. There were 16 primary NPC organoids and 13 recurrent NPC organoids. The success rate of culture of primary and recurrent NPC organoids was 47.06% and 81.25%, respectively. The success rate of culture was mainly related to tissue quality and size, specimen pollution, etc. (P= 0.002). 2. The 3D cultures were identified as NPC organoids. The pathological characteristics of HE staining of 3D NPC cultures were consistent with those of parental tumor tissues, which had typical nuclear atypia. The markers, CD133/CD44/CD47/BMI-1 and EBER, were all positivelv expressed in both 3D cultures and parent tumor tissues.
Conclusions
We have successfully established a NPC organoid model which provides a good reference for future study of the molecular mechanism of NPC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Li Gang.
Funding
Nanfang Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session